Business
Immunovant to Host Virtual R&D Day on March 30, 2022
Event will feature six key opinion leaders with expertise in thyroid eye disease, myasthenia gravis, warm autoimmune hemolytic anemia, and cholesterol
About this update from Immunovant, Inc.
[{"type":"text","content":"Event will feature six key opinion leaders with expertise in thyroid eye disease, myasthenia gravis, warm autoimmune hemolytic anemia, and cholesterol management\nNEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it will host a virtual R&D event on Wednesday, March 30, 2022, from 9:00 AM ET to 11:00 AM ET. Immunovant’s R&D event will include discussions with company management and key opinion leaders in thyroid eye disease, myasthenia gravis, warm autoimmune hemolytic anemia, and cholesterol management. Discussions will focus on the current treatment landscape for these indications as well as batoclimab’s (IMVT-1401) broad potential to address the unmet needs in target patient populations. New analyses from the Phase 2b study of batoclimab in thyroid eye disease will be presented as well as data from an ongoing, placebo-controlled Phase 1 study evaluating the co-administration of batoclimab and atorvastatin. Featured speakers will include: Michael Davidson, MD, Professor and Director of the Lipid Clinic at the University of Chicago, Pritzker School of MedicineGeorge Kahaly, MD, PhD, Professor of Medicine and Endocrinology / Metabolism at the Johannes Gutenberg University (JGU) Medical Center Department of Medicine | ORPHAN Disease Center for Graves’ Orbitopathy and Autoimmune PolyendocrinopathyAndrea Kossler, MD, FACS, Director, Oculoplastic Plastic Surgery & Orbital Oncology and Assistant Professor of Ophthalmology at Byers Eye Institute at Stanford UniversityKatherine Ruzhansky, MD, MS, Clinical Neurologist, Associate Professor of Neurology, and Director of the EMG Lab at the Medical University of South CarolinaNicholas Silvestri, MD, FAAN, Clinical Neurologist, Associate Professor of Neurology, and Assistant Dean for Student and Academic Affairs at the University of BuffaloDavid Tucker MB ChB, BSc, MD MRCP, FRCPath, Consultant Haematologist, Blood Transfusion and Patient Blood Management Lead, and NIHR CRN Regional Subspecialty Lead for Malignant and Non-Malignant Haematology at Royal Cornwall NHS Trust Following the formal presentations, company management will participate in a live question and answer session. To attend the event, please register at: Immunovant R&D...